Sponsored AstraZeneca To Raise Share Buyback By $1B AstraZeneca is seeking to add an additional $1 billion to its share buy-back program this year. July 28, 2011
Sponsored AstraZeneca Puts $100M More Into VC Unit Global pharmaceutical firm AstraZeneca has invested an additional $100 million into its venture capital arm MedImmune Ventures. November 29, 2011
Sponsored PE Firms Eye $2B Astra Tech Auction Private equity firms are planning to bid for AstraZeneca’s dental and medical devices unit, Astra Tech. February 25, 2011
This content is from: Portfolio Michael Pragnell of Syngenta: Green devolution This spin-off of AstraZeneca and Novartis represents a whole new approach to the risky but potentially remunerative agricultural technology business. And it's growing like GM wheat. August 09, 2004
This content is from: Research The 2015 All-Europe Research Team: Pharmaceuticals, No. 2: Andrew Baum & team Vaulting from runner-up to second place — the firm’s highest ranking to date — is the four-strong Citi troupe piloted by Andrew Baum. February 18, 2015
This content is from: Portfolio Ben Thorpe Helps Keep Goldman’s Health M&A Franchise in Top Shape Goldman Sachs’ head of health care investment banking for EMEA counts pharmaceuticals giants AstraZeneca and Novartis among his clients. By David Rothnie June 22, 2015
